CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM050853
035-os BibID:PMID:23293933
Első szerző:Bánáti Miklós (neurológus, Pécs)
Cím:Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system / M. Banati, P. Csecsei, E. Koszegi, H. H. Nielsen, G. Suto, L. Bors, A. Trauninger, T. Csepany, C. Rozsa, G. Jakab, T. Molnar, A. Berthele, S. R. Kalluri, T. Berki, Z. Illes
Dátum:2013
ISSN:1351-5101
Megjegyzések:Antibodies against gastrointestinal antigens may indicate altered microbiota and immune responses in the gut. Recent experimental data suggest a connection between gastrointestinal immune responses and CNS autoimmunity. METHODS: Antibodies against gliadin, tissue transglutaminase (tTG), intrinsic factor (IF), parietal cells (PC) and Saccharomyces cerevisiae (ASCA) were screened in the sera of 45 patients with AQP4-seropositive neuromyelitis optica (NMO) and NMO spectrum diseases (NMO/NMO-SD), 17 patients with AQP4-seronegative NMO, 85 patients with clinically definite multiple sclerosis (MS), and 48 healthy controls (HC). RESULTS: Thirty-seven percentages of patients with AQP4-seropositive NMO/NMO-SD and 28% of patients with MS had at least one particular antibody in contrast to 8% of HC (P < 0.01, respectively). Antibodies were most common (46%) in AQP4-seropositive myelitis (P = 0.01 versus HS, P = 0.05 versus MS). Anti-gliadin and ASCA were more frequent in the AQP4-seropositive NMO-spectrum compared to controls (P = 0.01 and P < 0.05, respectively). CONCLUSION: Antibody responses against gastrointestinal antigens are common in MS and AQP4-seropositive NMO/NMO-SD, especially in longitudinally extensive myelitis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
anti-Saccharomyces cerevisiae
aquaporin 4
gliadin
intrinsic factor
multiple sclerosis
myelitis
neuromyelitis optica
optic neuritis
parietal cell
transglutaminase
Megjelenés:European Journal of Neurology. - 20 : 11 (2013), p. 1492-1495. -
További szerzők:Csécsei Péter (1992-) (neurológus) Kőszegi E. (neurológus, Pécs) Nielsen, Helle H. Sütő Gábor Bors László (Neurológus, Pécs) Trauninger Anita (Pécs orvos) Csépány Tünde (1956-) (neurológus, pszichiáter) Rózsa Csilla Jakab Gabriella Molnár T. Berthele, A. Kalluri, Sudhakar Reddy Berki Tímea Illés Zsolt (neurológus, Pécs)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM103013
035-os BibID:(Wos)000597939700001 (Scopus)85097297540
Első szerző:Berger, Thomas
Cím:Factors influencing daily treatment choices in multiple sclerosis : practice guidelines, biomarkers and burden of disease / Berger Thomas, Adamczyk-Sowa Monika, Csépány Tünde, Fazekas Franz, Fabjan Tanja Hojs, Horáková Dana, Ledinek Alenka Horvath, Illes Zsolt, Kobelt Gisela, Jazbec Sasa Sega, Klímová Eleonóra, Leutmezer Fritz, Rejdak Konrad, Rozsa Csilla, Sellner Johann, Selmaj Krzysztof, Stourac Pavel, Szilasiová Jarmila, Turcáni Peter, Vachová Marta, Vanecková Manuela, Vécsei László, Havrdová Eva Kubala
Dátum:2020
ISSN:1756-2856 1756-2864
Megjegyzések:At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and 2019 factors influencing daily treatment choices in MS, especially practice guidelines, biomarkers and burden of disease, were discussed. The heterogeneity of MS and the complexity of the available treatment options call for informed treatment choices. However, evidence from clinical trials is generally lacking, particularly regarding sequencing, switches and escalation of drugs. Also, there is a need to identify patients who require highly efficacious treatment from the onset of their disease to prevent deterioration. The recently published European Committee for the Treatment and Research in Multiple Sclerosis/European Academy of Neurology clinical practice guidelines on pharmacological management of MS cover aspects such as treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and are based on expert consensus statements. However, the recommendations constitute an excellent framework that should be adapted to local regulations, MS center capacities and infrastructure. Further, available and emerging biomarkers for treatment guidance were discussed. Magnetic resonance imaging parameters are deemed most reliable at present, even though complex assessment including clinical evaluation and laboratory parameters besides imaging is necessary in clinical routine. Neurofilament-light chain levels appear to represent the current most promising non-imaging biomarker. Other immunological data, including issues of immunosenescence, will play an increasingly important role for future treatment algorithms. Cognitive impairment has been recognized as a major contribution to MS disease burden. Regular evaluation of cognitive function is recommended in MS patients, although no specific disease-modifying treatment has been defined to date. Finally, systematic documentation of real-life data is recognized as a great opportunity to tackle unresolved daily routine challenges, such as use of sequential therapies, but requires joint efforts across clinics, governments and pharmaceutical companies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Therapeutic Advances in Neurological Disorders. - 13 (2020), p. 1-13. -
További szerzők:Adamczyk-Sowa, Monika Csépány Tünde (1956-) (neurológus, pszichiáter) Fazekas, Franz Fabjan, Tanja Hojs Horakova, Dana Horváth Ledinek, Alenka Illés Zsolt (neurológus, Pécs) Kobelt, Gisela Jazbec, Sasa Sega Klimova, Eleonora Leutmezer, Fritz Rejdak, Konrad Rózsa Csilla Sellner, Johann Selmaj, Krzysztof Stourac, Pavel Szilasiova, Jarmila Turčáni, Peter Vachova Márta Vanecková, Manuela Vécsei László (1954-) (neurológus) Havrdova, Eva
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM058156
Első szerző:Csépány Tünde (neurológus, pszichiáter)
Cím:Klinikai neuroimmunológia / Csépány T., Illés Z.
Dátum:2014
Megjelenés:2. átd., bőv. kiad. Budapest : Budapest Professional Publishing Scientific Hungary Kiadó, 2014
Terjedelem:434 p.
ISBN:978 615 508 9039
Tárgyszavak:Orvostudományok Klinikai orvostudományok szakkönyv
További szerzők:Illés Zsolt (neurológus, Pécs)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM103012
035-os BibID:(Scopus)85102939985 (WOS)000631262400001 (cikkazonosító)611597
Első szerző:Hayden Zsófia
Cím:Clinical Characteristics and Outcome of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis Patients in a National Cohort / Hayden Zsófia, Bóné Beáta, Orsi Gergely, Szots Monika, Nagy Ferenc, Csépány Tünde, Mezei Zsolt, Rajda Cecília, Simon Diána, Najbauer József, Illes Zsolt, Berki Timea
Dátum:2021
ISSN:1664-2295
Megjegyzések:Background: In our previous single-center study of autoimmune encephalitis (AE) related autoantibody test results we found positivity in 60 patients out of 1,034 with suspected AE from 2012 through 2018 as part of a Hungarian nationwide program. In our current multicenter retrospective study, we analyzed the clinical characteristics and outcome of AE patients with positive neuronal cell surface autoantibody test results. Methods: A standard online questionnaire was used to collect demographic and clinical characteristics, laboratory and imaging data, therapy and prognosis of 30 definitive AE patients in four major clinical centers of the region. Results: In our study, 19 patients were positive for anti-NMDAR (63%), 6 patients (20%) for anti-LGI1, 3 patients for anti-GABABR (10%) and 3 patients for anti-Caspr2 (10%) autoantibodies. Most common prodromal symptoms were fever or flu-like symptoms (10/30, 33%). Main clinical features included psychiatric symptoms (83%), epileptic seizures (73%) and memory loss (50%). 19 patients (63%) presented with signs of central nervous system (CNS) inflammation, which occurred more frequently in elder individuals (p = 0.024), although no significant differences were observed in sex, tumor association, time to diagnosis, prognosis and immunotherapy compared to AE patients without CNS inflammatory markers. Anti-NMDAR encephalitis patients were in more severe condition at the disease onset (p = 0.028), although no significant correlation between mRS score, age, sex and immunotherapy was found. 27% of patients (n = 8) with associated tumors had worse outcome (p = 0.045) than patients without tumor. In most cases, immunotherapy led to clinical improvement of AE patients (80%) who achieved a good outcome (mRS ? 2; median follow-up 33 months). Conclusion: Our study confirms previous publications describing characteristics of AE patients, however, differences were observed in anti-NMDAR encephalitis that showed no association with ovarian teratoma and occurred more frequently among young males. One-third of AE patients lacked signs of inflammation in both CSF and brain MRI, which emphasizes the importance of clinical symptoms and autoantibody testing in diagnostic workflow for early introduction of immunotherapy, which can lead to favorable outcome in AE patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Neurology. - 12 (2021), p. 1-11. -
További szerzők:Bóné Beáta Orsi Gergely Szots Monika Nagy Ferenc (neurológus Kaposvár) Csépány Tünde (1956-) (neurológus, pszichiáter) Mezei Zsolt (1979-) (neurológus) Rajda Cecília Simon Diána Najbauer József Illés Zsolt (neurológus, Pécs) Berki Tímea
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM067750
Első szerző:Kovács Katalin T. (orvos, Pécs)
Cím:Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus : a preliminary study / Katalin T. Kovacs, Sudhakar R. Kalluri, Antonio Boza-Serrano, Tomas Deierborg, Tunde Csepany, Magdolna Simo, Laszlo Rokusz, Attila Miseta, Nicolas Alcaraz, Laszlo Czirjak, Timea Berki, Tihamer Molnar, Bernhard Hemmer, Zsolt Illes
Dátum:2016
Megjegyzések:Background: Neuromyelitis optica (NMO)?systemic lupus erythematosus (SLE) association is a rare condition characterized by multiple autoantibodies.Objective: To examine if, during the evolution of NMO, anti-AQP4 responses are part of polyclonal B cell activation, and if T cell responses contribute.Methods: In 19 samples of six patients who developed NMO during SLE, we examined the correlation of AQP4-IgG1 and IgM with (i) anti-MOG IgG and IgM, (ii) anti-nuclear, anti-nucleosome and antidsDNA IgG antibodies, (iii) cytokines and chemokines in the serum and (iv) longitudinal relation to NMO relapses/remission.Results: AQP4-IgG1 was present 1?2?5 years before the first NMO relapse. During relapse, AQP4-IgG1, ANA, anti-dsDNA and anti-nucleosome antibodies were elevated. Anti-MOG IgG/IgM and AQP4-IgM antibodies were not detected. AQP4-IgG1 antibodies correlated with concentration of anti-nucleosome, IFN-?,interferon-gamma-induced CCL10/IP-10 and CCL17/TARC (p<0.05, respectively). CCL17/TARC correlated with levels of anti-nucleosome and anti-dsDNA (p<0.05, respectively). Compared to healthy subjects, concentration of IFN-? and CCL17/TARC was higher in NMO/SLE (p<0.05).Conclusions: AQP4-IgG1 antibodies are present in the sera years before the first NMO attack in patients with SLE; elevation of anti-AQP4 is part of a polyclonal B cell response during NMO relapses; in spite of multiple autoantibodies in the serum, MOG antibodies were not present; Th1 responses accompany autoantibody responses in NMO/SLE.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
AQP4
SLE
myelin oligodendrocyte glycoprotein
IL-17
IP-10
Th1
Th17
Megjelenés:Multiple Sclerosis Journal 22 : 9 (2016), p. 1192-1201. -
További szerzők:Kalluri, Sudhakar Reddy Boza-Serrano, Antonio Deierborg, Tomas Csépány Tünde (1956-) (neurológus, pszichiáter) Simó Magdolna Rókusz László Miseta Attila Alcaraz, Nicolas Czirják László Berki Tímea Molnár Tihamér (1992-) (általános orvos) Hemmer, Bernhard Illés Zsolt (neurológus, Pécs)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM085750
Első szerző:Nielsen, Helle H.
Cím:Integrin and IL-16/IL-23 biomarker clusters differentiate AQP4-IgG+ NMO spectrum disorders, relapsing-remitting MS and healthy controls / H. H. Nielsen, S. Kalluri, T. Frisch, T. Sejbaek, G. Dale, T. Petersen, Csépány Tünde, Lovas Gábor, M. Simo, P. Diószeghy, J. Baumbach, B. Hemmer, Z. Illes
Dátum:2017
ISSN:1352-4585
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Multiple Sclerosis. - 23 (2017), p. 685. -
További szerzők:Kalluri, Sudhakar Reddy Frisch, T. Sejbaek, Tobias Dale, George L. Petersen, Thor Csépány Tünde (1956-) (neurológus, pszichiáter) Lovas Gábor Simó Magdolna Diószeghy Péter (1948-) (ideg- és elmeszakorvos) Baumbach, J. Hemmer, Bernhard Illés Zsolt (neurológus, Pécs)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM077070
035-os BibID:(cikkazonosító)e0139659
Első szerző:Nielsen, Helle H.
Cím:The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis : a Clinical Proteome Study / Helle H. Nielsen, Hans C. Beck, Lars P. Kristensen, Mark Burton, Tunde Csepany, Magdolna Simo, Peter Dioszeghy, Tobias Sejbaek, Manuela Grebing, Niels H. H. Heegaard, Zsolt Illes
Dátum:2015
ISSN:1932-6203 1932-6203
Megjegyzések:OBJECTIVES: Inflammatory demyelinating diseases of the CNS comprise a broad spectrum of diseases like neuromyelitis optica (NMO), NMO spectrum disorders (NMO-SD) and multiple sclerosis (MS). Despite clear classification criteria, differentiation can be difficult. We hypothesized that the urine proteome may differentiate NMO from MS. METHODS: The proteins in urine samples from anti-aquaporin 4 (AQP4) seropositive NMO/NMO-SD patients (n = 32), patients with MS (n = 46) and healthy subjects (HS, n = 31) were examined by quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) after trypsin digestion and iTRAQ labelling. Immunoglobulins (Ig) in the urine were validated by nephelometry in an independent cohort (n = 9-10 pr. groups). RESULTS: The analysis identified a total of 1112 different proteins of which 333 were shared by all 109 subjects. Cluster analysis revealed differences in the urine proteome of NMO/NMO-SD compared to HS and MS. Principal component analysis also suggested that the NMO/NMO-SD proteome profile was useful for classification. Multivariate regression analysis revealed a 3-protein profile for the NMO/NMO-SD versus HS discrimination, a 6-protein profile for NMO/NMO-SD versus MS discrimination and an 11-protein profile for MS versus HS discrimination. All protein panels yielded highly significant ROC curves (AUC in all cases >0.85, p?0.0002). Nephelometry confirmed the presence of increased Ig-light chains in the urine of patients with NMO/NMO-SD. CONCLUSION: The urine proteome profile of patients with NMO/NMO-SD is different from MS and HS. This may reflect differences in the pathogenesis of NMO/NMO-SD versus MS and suggests that urine may be a potential source of biomarkers differentiating NMO/NMO-SD from MS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Plos One. - 10 : 10 (2015), p. 1-15. -
További szerzők:Beck, Hans C. Kristensen, Lars P. Burton, Mark Csépány Tünde (1956-) (neurológus, pszichiáter) Simó Magdolna Diószeghy Péter (1948-) (ideg- és elmeszakorvos) Sejbaek, Tobias Grebing, Manuela Heegaard, Niels H. H. Illés Zsolt (neurológus, Pécs)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM116231
035-os BibID:(cikkazonosító)183 (scopus)85164167253 (wos)001022417900001
Első szerző:Rajda Cecília
Cím:Treatment of relapsing multiple sclerosis in Hungary : consensus recommendation from the Hungarian neuroimmunology society / Rajda Cecilia, Rózsa Csilla, Mike Andrea, Lovas Gábor, Mezei Zsolt, Jakab Gábor, Ács Péter, Rum Gábor, Simó Magdolna, Jobbágy Zita, Bíró Zita, Trauninger Anita, Imre Piroska, Mátyás Klotild, Deme István, Illés Zsolt, Csepany Tunde
Dátum:2023
ISSN:1750-1172
Megjegyzések:Multiple sclerosis (MS) may impact quality of life, careers and family plans of the affected individuals. The current treatments with disease modifying therapies aim to prevent people with MS (pwMS) from disability accumulation and progression. Different countries have different reimbursement policies resulting in inequalities in patient care among geographical regions. Access to anti-CD20 therapies for relapsing MS is restricted in Hungary because therapy of individual cases only is reimbursed. In the light of the latest research and national guidelines, 17 Hungarian MS experts agreed on 8 recommendations regarding relapsing pwMS using the Delphi round method. Strong agreement (>80%) was achieved in all except one recommendation after three rounds, which generated a fourth Delphi round. The experts agreed on treatment initiation, switch, follow-up and discontinuation, as well as on special issues such as pregnancy, lactation, elderly population, and vaccination. Well-defined national consensus protocols may facilitate dialogue between policymakers and healthcare professionals and thus contribute to better patient care in the long run.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Consensus
Multiple sclerosis
Recommendation
Treatment
Megjelenés:Orphanet Journal of Rare Diseases. - 18 : 1 (2023), p. 1-8. -
További szerzők:Rózsa Csilla Mike Andrea (neurológus, Pécs) Lovas Gábor Mezei Zsolt (1979-) (neurológus) Jakab Gábor Ács Péter Rum Gábor Simó Magdolna Jobbágy Zita Bíró Zita Trauninger Anita (Pécs orvos) Imre Piroska Mátyás Klotild Deme István Illés Zsolt (neurológus, Pécs) Csépány Tünde (1956-) (neurológus, pszichiáter)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.